The CEO of an Australian IT startup has designed a personalized cancer vaccine for his dog diagnosed with a terminal illness using artificial intelligence (AI) and confirmed its therapeutic effects.

With no biology degree and just $3,000, he designed a personalized mRNA vaccine in a world first. Moderna and Merck are ...

The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical ...

It would send a troubling message that politics will determine which medical technologies Idahoans are allowed to use. | ...

Public health experts criticize Retsef Levi’s studies ahead of a key vaccine advisory meeting ...

The company’s cash and securities nearly equal its market value, meaning investors aren’t paying much for the Covid franchise and a pipeline focused on cancer treatments.

The Exton-based company provides packaging and related services for injectable drugs. Green led West's pandemic response, supplying packaging for vaccine distribution worldwide.

"It's probably one of the most egregious demonstrations of government overreach imaginable." | Opinion ...

Immunis Inc. has struck a licensing deal with Japanese material manufacturer Toray Industries Inc. to develop a potential treatment for Parkinson’s-associated involuntary movement.

The move comes as BioNTech shifts to being a multiproduct commercial biotech, allowing Ugur Sahin and Özlem Türeci to transition back into research on next-generation mRNA therapeutics.

The leadership changes arrive as BioNTech reported a 57% rise in net losses for 2025.